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Abstract 
Background: The current study was designed to evaluate immune responses induced 
by DNA vaccines encoding 8-kDa subunit of antigen B (HydI) of Echinococcus granulosus 
and murine interleukin 12 (IL-12) as genetic adjuvants in BALB/c mice. 
Methods: Expression plasmid pcDNA3.1 containing HydI (pcHyd1) as vaccine along 
with the murine interleukin 12 (pcMIL12) as adjuvant were used. Thirty-five mice in 
the five experimental groups received PBS, empty pcDNA3.1, pcHydІ, pcMIL-12, and 
pcHydІ+ pcMIL-12 in days zero, 14th and 28th. Two weeks after the last immunization, 
evaluation of the immune response was performed by evaluating the proliferation of 
splenic lymphocytes, IFN-γ and IL-4, determination of IgG isotyping titer.  
Results: Mice that received the pcHydI+pcMIL12 exhibited higher levels of lympho-
cyte proliferation compared to mice that received the pcHydI alone (P<0.001), and 
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produced significantly more IFN-γ in comparison to other groups (P< 0.001). In addi-
tion, they produced significantly less IL-4 than mice receiving the PBS and the empty 
plasmid (P<0.023). The IgG2a levels were clearly higher in pcHydI+pcMIL12 group in 
comparison with the groups of pcHydI alone, empty plasmid, and PBS. In contrast, 
IgG1 was elevated in the group of pcHydI.  
Conclusion: Co-delivery of IL-12 with DNA encoding 8-kDa subunit of antigen B 
was effective significantly in inducing the immune response in mice. 
Introduction 
 
ystic echinococcosis (CE), also known 
as hydatid disease, is a zoonotic and 
helminthic disease with worldwide dis-
tribution caused by the larval stage 
of Echinococcus granulosus (1). It is found in sev-
en continents, with the highest prevalence in 
parts of Eurasia (especially Mediterranean and 
Middle Eastern countries and China), north 
and east Africa, Australia, and South America, 
where human incidence rates are as high as 50 
per 100,000 person-years (2-4). This disease 
has a significant impact on both human and 
animal health and causes important public 
health-economic problem with annual esti-
mated cost around three billion US dollars in 
endemic areas (5, 6). 
Echinococcosis is preventable (7). Even al-
though hydatid control programs have been 
successful in some countries but the world-
wide distribution and the important socio-
economic problem of hydatid cyst has not se-
riously changed (8). Unfortunately, in many 
regions hydatid control programs is not appli-
cable and available for some reason such as 
the budget deficit, foreign and domestic wars, 
mismanagement, the issues of security and 
political-social-environmental changes (9, 10).  
Vaccination is the most effective and effi-
cient manner for diseases prevention caused 
by infectious agents (11). Mathematical mod-
els show approaches to control and preven-
tion of hydatidosis, including an effective vac-
cine for intermediate host and more effective 
anti-parasitic treatments in definitive host (11, 
12). Genetic/DNA vaccines are the new gen-
eration of vaccines that have high potential to 
stimulate both cellular and humoral immune 
response as well as to polarize T-cell helper 
toward type 1 or type 2 by direct injection 
plasmid expressing the DNA sequence of an-
tigen(s) into appropriate tissues of animal (13).  
Antigen B (AgB), major antigen in hydatid 
cyst fluid, is a thermo-stable lipoprotein with a 
molecular mass of 160 kDa that separate in 
SDS-PAGE into three bands of 8-12, 16, and 
24-kDa; in fact AgB is a combination of mo-
nomers 8-kDa. AgB is encoded by at least five 
main gene clusters, EgAgB1-5 (14, 15).  
The current study was designed to evaluate 
of induced immune responses by DNA vac-
cines encoding 8-kDa subunit of antigen B 
(HydI) of E. granulosus and mouse interleukin-
12 (IL-12) as genetic adjuvants in BALB/c 
mice. 
 
Materials and Methods 
 
Mice 
Thirty-five female BALB/c mice of 6-8 
week age were purchased from Razi Institute 
(Karaj, Iran). Mice were maintained under 
specific-pathogen-free, feeding and rearing 
standard conditions. All experiments were 
performed according to the Animal Care and 
Use Protocol of Tehran University of Medical 
Sciences (Tehran, Iran) and the Ethical Com-
mittee of the university approved the study. 
 
Plasmid construction 
The eukaryotic expression plasmid 
pcDNA/Hyd1(pcHydI) has been previously 
constructed and expressed in eukaryotic cells 
successfully in our laboratory (16).  
C 
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Mouse IL-12 was synthesized and sub-
cloned into the dual promoter IL-12p70 ex-
pression vector pcDNA3.1 (pcMIL-12) (Cin-
nagen, Tehran, Iran). The mouse IL-12 p35 
subunit (accession number NM_001303244.1) 
is expressed under control of the human CMV 
promoter and bovine growth hormone (BGH) 
polyadenylation signal, while the mouse IL-12 
p40 subunit (accession number 
NM_001159424.2) is expressed under control 
of the simian CMV promoter and simian virus 
40 (SV40) polyadenylation signal.  
The NIH 3T3 cells, mouse embryonic fi-
broblast cell line, transfected with plasmid 
pcMIL-12 were tested for the presence of IL-
12 protein by antibody capture ELISA. The 
plasmid DNA was prepared using the Qiagen 
Plasmid DNA Purification Kit (Qiagen, USA) 
according to the manufacturer’s protocol. 
 
DNA immunization  
Five groups of mice (seven per group) were 
bilaterally inoculated intramuscularly in the 
thigh skeletal muscle with 100 μg of plasmid 
DNA suspended in 100 μl sterile PBS, whe-
reas control mice received PBS alone. Group I 
was injected with PBS as control, group II 
with empty pcDNA3.1 vector also as control, 
group III with pcHydI, group IV with 
pcMIL12, group V with pcHydI plus 
pcMIL12 (50 μg each). Every mouse was in-
jected with same protocol on days zero, 14th 
and 28th. At two weeks post the last vaccina-
tion, blood samples were collected from the 
heart for serological tests and the spleens of 
the mice were removed under sterile condi-
tions for lymphocyte proliferation assay and 
cytokine measurements.  
 
Lymphocyte proliferation assays 
The lymphocyte proliferation rate was 
measured using an MTT (3[4,5-
dimethylthiazol-2-ml]-2,5-diphenyltetrazolium 
bromide; thiazolyl-blue, Sigma, Germany) dye 
assay, two weeks after the last immunization. 
Briefly, splenocyte suspensions were prepared 
from each group of mice by squishing the 
spleens through a wire mesh under sterile 
conditions. After the red blood cells was re-
moved using ammonium chloride. Splenocytes 
were resuspended in RPMI 1640 medium 
supplemented with 10% FCS. One hundred 
ml of diluted cell suspensions were then plated 
in 96-well flat-bottom culture plates at a densi-
ty of 1×1010 cells per ml in each well and cul-
tured with concanavalin A (Con A; 5 μg/ml; 
Sigma; positive control), or medium alone 
(negative control) or 10 μl of the Ag B at 
37 °C with 5% CO2 (17). 
After 72 h, cell proliferation was determined 
using an MTT assay (17). Briefly, each well 
was added with 20 μl of MTT and the plates 
were further incubated at 37 ◦C for 4 h. then, 
the supernatant was harvested from each well 
and formazan crystals were solubilized by add-
ing 100 ml of dimethyl sulfoxide (DMSO). 
After 20 min, the absorbance of each well was 
measured at a wavelength of 540 nm. Stimula-
tion indices were determined and expressed as 
differences between the absorbance of treated 
and untreated wells.  
 
Cytokine assays 
To evaluate cytokines levels, splenocytes 
from immunized mice were cultured and res-
timulated in vitro with 10 μl of the Ag B sus-
pension as described for the lymphoprolifera-
tion assay. Cell-free supernatants were re-
moved and assayed for interleukin-4 (IL-4), 
and for gamma-interferon (IFN-γ) activity at 
72 h. IFN-γ and IL-4, were measured using 
ELISA kits according to the manufacturer’s 
instructions (eBscience, USA). Cytokine con-
centrations were determined by reference to 
standard curves constructed with known 
amounts of mouse recombinant IFN-γ and 
IL-4. All assays were performed in triplicate. 
 
Antibody assays 
The humoral IgG1 and IgG2a subclass in 
serum samples, which were taken in two 
weeks after the final immunization, were 
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measured by ELISA using 96-well micro-titer 
plates (18). In brief, following coating micro-
titer plates at 4 °C overnight with 100 µl Ag B 
(with the concentration of 10 µg/ml) in 0.05 
M bicarbonate buffer, pH 9.6, the plates were 
washed with PBS containing 0.05% Tween 20 
(PBST-20), pH 7.4, 2 times and non-specific 
binding sites were blocked with PBS contain-
ing 5% FCS for 2 h at 37 °C. After washing 
the plates with PBST, sera were diluted in 1% 
PBST-20 (1:100) and added to each well. 
Plates were incubated for 2 h at room temper-
ature, washed three times and incubated with 
HRP-conjugated rabbit anti-mouse IgG2a, 
IgG1. After sufficient washes, the reaction 
was developed by adding 200 ml of 
TMB/H2O2 substrate. The reaction was ter-
minated by the addition of 50 ml of 2.0N 
H2SO4 and the optical density (OD) was read 
at 450 nm in a microplate reader (Thermo 
Scientific Multiskan FC, USA). All assays were 
performed in triplicate. 
 
Statistical analysis 
The lymphocyte proliferation assay and cy-
tokine and antibody levels were analyzed by 
one-way analysis of variance (ANOVA) tech-
nique followed by Tukey’s post-test. Signific-
ance was set at P<0.05. Using SPSS 16 (SPSS 
Inc., Chicago, IL, USA). 
 
Results  
 
Lymphocyte proliferation 
Lymphocyte proliferation is generally consi-
dered a measure of cell-mediated immunity; 
therefore, Ag B-specific lymphocytic prolifera-
tion was evaluated using an MTT assay in two 
weeks after the last immunization. As shown 
in Fig. 1, the two groups immunized with 
pcHydI plus pcMIL12, and pcHydI alone, in-
creased lymphocyte response, compared with 
the negative control (which received only 
PBS) (P<0.001). Mice that received the pcHy-
dI plus pcMIL12 exhibited higher levels of 
lymphocyte proliferation compared to mice 
that received the pcHydI alone (P< 0.001). 
 
Cytokine pattern 
We investigated the effect of pcHydI with 
and without co-injection of pcMIL12 on 
changes in Th1 and Th2 phenotypes. As 
shown in Fig. 2, immunized mice with the 
pcHydI plus pcMIL12 produced significantly 
more IFN-γ (Th1-type) in comparison to mice 
that received either PBS, the pcHydI alone, 
the pcMIL12 alone or empty plasmid (for all 
P<0.001). 
In contrast, lymphocytes from vaccinated 
mice with the pcHydI alone produced larger 
amounts of IL-4 (Th2-type) than mice that 
received PBS, the pcHydI plus pcMIL12, the 
pcMIL12 alone or empty plasmid (for all 
P<0.001).   
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Fig. 1: Splenocyte proliferation assay, spleens from individual mice (seven per group) was removed and lym-
phocyte proliferation was evaluated by the MTT method. Values represent the mean ± SE. SI=Stimulation 
Index. Statistically significant differences (P<0.05) are indicated by (*) compared with control, plasmid, 
pcHydӏ, IL-12 or pcHydӏ/IL-12 group 
 
Immunized mice with the pcHydI+ pcMIL12 
produced significantly loss IL-4 than mice re-
ceiving the PBS and the empty plasmid (for 
both P<0.023). The results show that the IL-4 
cytokine levels were decreased in the presence 
of IL-12.  
Antibody titer 
Considering that IFN-γ and IL-4 are impor-
tant to conduct immunoglobulin class switch-
ing for IgG2a and IgG1, respectively, the pro-
duction of antigen-specific immuneglobulin 
isotypes were evaluated in the mice at two 
weeks after final immunization. 
 
 
 
Fig. 2: Comparison of production levels of IFN-γ from splenocytes in groups control (PBS and empty plas-
mid), pcHydI+pcMIL12 and pcHydI and pcMIL12. Values are shown as the mean± SE. Statistically signifi-
cant differences (P < 0.05) are indicated by (*) compared with control, plasmid, pcHydӏ, IL-12 or pcHydӏ/IL-
12  group 
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Fig. 3: Comparison of production levels of IL-4 from splenocytes in groups control (PBS and empty plasmid), 
pcHydI+pcMIL12 and pcHydI and pcMIL12. Values are shown as the mean± SE. Statistically significant dif-
ferences (P < 0.05) are indicated by (*) compared with control, plasmid, pcHydӏ, IL-12 or pcHydӏ/IL-12  
group 
 
The IgG2a levels, as shown in Fig. 4, were 
clearly higher in the sera of mice treated with 
the pcHydI plus pcMIL12 in comparison with 
mice that received the pcHydI alone, empty 
plasmid and PBS (P<0.002, P<0.001, P<0.001, 
respectively). The vaccinated mice with the 
pcHydI plus pcMIL12 had more IgG2a com-
pared to the mice that received the pcMIL12; 
however, the differences were not statistically 
significant. 
In contrast, antigen-specific IgG1 was ele-
vated in the group of mice that received the 
pcHydI alone and in comparison with groups 
receiving pcHydI plus pcMIL12, pcMIL12 
alone, empty plasmid and PBS(control) had 
significant difference (for all groups P<0.001) 
(Fig. 5).  
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Fig. 4: The levels of IgG2a antibody in the sera obtained two weeks after the last immunization were deter-
mined. Values represent the mean ± SE. Sera were used at 1/100 dilutions. O.D., optical density at 450 nm. 
Statistically significant differences (P < 0.05) are indicated by (*) compared with control, plasmid, pcHydӏ, IL-
12 or pcHydӏ/IL-12  group 
 
 
 
Fig. 5: The levels of IgG1 antibody in the sera obtained two weeks after the last immunization were deter-
mined. Values represent the mean ± SE. Sera were used at 1/100 dilutions. O.D., optical density at 450 nm. 
Statistically significant differences (P < 0.05) are indicated by (*) compared with control, plasmid, pcHydӏ, IL-
12 or pcHydӏ/IL-12  group 
 
Discussion  
 
Vaccination of intermediate host is one of 
the main ways to control of hydatid cyst dis-
ease (19). In order to access an appropriate 
vaccine against hydatid cyst, many studies 
were performed on various-parasite antigens 
alone or in combination with different adju-
vant such as genetic adjuvant (20-22).  
DNA vaccines have several interesting fea-
tures for researchers, such as long-lasting im-
munity, priming both cellular and humoral 
specific immune responses, and production of 
the native form of a given antigen. In addition, 
the production costs are low and they are easy 
and quick to product (23). After the first re-
port of successful DNA immunization (24), 
great efforts have been done in developing 
DNA vaccines for parasitic infections. 
In hydatid cyst disease, immunity induced is 
complex and containing both antibody and 
cellular components. However, protective 
outcome is corresponding to Th1 responses, 
while Th2 responses not only non-protective 
but also are associated with progress of the 
disease (25). Therefore, the potency of the 
antigen to shift the immune response to spe-
cifically the T helper (Th) subtype is important 
in vaccine design against hydatid cyst agent. 
Here, for the first time the potential of Ag B 
(pcHyd1) alone and in compound with murine 
interleukin (pcMIL-12) to induce protective 
immune response was investigated in mouse 
models. 
Overall, DNA vaccines produce a Th1 rather 
than Th2 type immune responses (13), but our 
results showed that the Ag B (pcHyd1) alone is 
adequately immunogenic and induce a mixture 
of humoral and cellular immunity but induce 
Th2 response more than Th1 response. This 
might be due to the nature of antigen B that 
has both B cell and T-cell epitopes. In mice 
that had been vaccinated with pcHyd1, levels 
of IL-4 and IgG1 signficantly increased in con-
trast to IFN-γ and IgG2a respectively. Antibo-
dies seem have little or no importance protec-
tion for host against infection by oncosphere of 
E. granulosus (8). In the current study, we ap-
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proved that antigen B is immunogenic but has 
potential to direct the immune system towards 
Th2 type. 
Due to lack of available research on the 
DNA vaccine of antigen B, our findings were 
compared to other studies that had been car-
ried out on parasitic antigens with same condi-
tions including; the amount of vaccine, labora-
tory animals, site of injection, repeated injec-
tion number and interval time. Comparisons 
showed that depending on the type epitope(s) 
into antigen, different results (cellular immuni-
ty, humoral or a combination of both) might 
be obtained (26-29).  
Although DNA vaccines have many advan-
tages, their ability in inducing immune res-
ponses in the absence of suitable adjuvants is 
poor (23). Enhancing and shifting immune 
response of vaccinated animal into Th1 or 
Th2 regulated profiles by the co-
administration of genetic adjuvants is one of 
the advantages of DNA vaccines (23). In this 
regard, numerous studies have been per-
formed on the effectiveness of co-
administration of Th1 cytokine-encoding 
plasmids, such as IL-2, IL-15, IL-18, IL-23, 
and IFN-γ (30-32). IL-12 is produced by acti-
vated antigen-presenting cells such as dendrit-
ic cells and macrophages. It facilitates the de-
velopment of Th1 responses and is a powerful 
inducer of IFN-γ production by T and NK 
cells (33). Hence, in this study IL-12 was used 
as genetic adjuvant to enhance immune re-
sponse to Ag B. 
Our observations indicated mice vaccinated 
with composed pcHydI plus pcMIL12 pro-
duce higher IFN-γ. The amount of IFN-γ in 
pcHydI-vaccinated mice certified that simul-
taneous injection of IL-12 with the pcHydI 
increased and expanded the Th1 cytokines 
responses but not Th2 cytokines like IL-4.  
IFN-γ promotes isotype switching towards 
IgG2 in mouse. Our results show that vacci-
nated mice with pcMIL12 with pcHydI signif-
icantly increased IgG2a production than im-
munized mice with pcHydI alone. This results 
show a shift toward a Th1 immune response. 
This finding is in accordance with other studies 
where co-administration of IL-12 and antigen-
encoding plasmid augmented the ability of vac-
cine to induce the production of IFN-γ and 
IgG2a against Toxoplasma gondii (34, 35). 
These results clearly indicate that pcMIL12 
is a powerful adjuvant that along with vaccine 
develops a strong Th1 polarization in the im-
mune response in mice. Other studies used 
murine IL12 as genetic adjuvant reported 
similar findings (36-39). 
 
Conclusion 
 
Co-delivery of IL-12 with DNA encoding the 
8-kDa subunit of antigen B hydatid cyst was 
effective in inducing Th1 type immune response. 
The higher titers of anti-antigen B IgG2a class 
antibodies plus the Th1 polarization response 
may be effective for protecting mice. Therefore, 
is complementary studies are suggested towards 
the use of Ag B-DNA vaccines combined with 
IL12 plasmid to protection against oncosphere 
of Echinococcus granulosus. 
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